Biocartis takes on lung cancer

June 21, 2016 News BioVox

Biocartis ups its arsenal once again. This time, the company behind the diagnostic Idylla™ platform adds a lung cancer assay to its ever growing menu of diagnostic tests.

Lung cancer comprises 13% of all cancers. The vast majority of these are known as non-small cell lung cancers, many with mutations in the gene encoding the epidermal growth factor receptor (EGFR). Biocartis’ newly launched Idylla™ EGFR Mutation Assay detects up to 53 EGFR mutations in only 150 minutes with 2 minutes of hands-on time. Comparable analyses suffer from a cumbersome workflow which can take several weeks.

With the EGFR Mutation Assay, Biocartis brings its 7th cartridge for the Idylla™ platform to the market. The 5 assays relevant in oncology now cover most of the known and frequently used biomarkers in cancer research and care.

Geert Maertens, Chief Scientific Officer of Biocartis, commented: “Our EGFR Mutation Assay truly is a unique test from various perspectives. Being by far the easiest and fastest test for EGFR mutations available, it detects a broader range of mutations compared to standard tests and only requires a small amount of sample. We see great potential in Europe as well as in Asia where EGFR mutations in NSCLC occur in up to 50% of patients. It is also a great solution both for large reference centers where this new assay is able to complement current workflows in a versatile, fast and cost-effective way, as well as for countries or regions where local accessibility to high precision EGFR testing is limited, or even non-existing. As such, we are convinced this assay will further boost the growth of our installed base of Idylla™ instruments across the globe.”

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter